Illumina, Inc. 2016 Form 10-K Summary
Business context and reporting period
Illumina provides sequencing- and array-based genetic analysis systems, consumables, software, and services for research, clinical genomics, reproductive health, oncology, consumer genomics, agrigenomics, and other markets. The filing covers the 52-week fiscal year ended January 1, 2017; fiscal 2015 comprised 53 weeks. The company reported Core Illumina and Consolidated VIEs segments, consisting primarily of GRAIL and Helix.
Key financial metrics
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Total revenue | $2.398 billion | $2.220 billion | Up 8% |
| Gross profit | $1.666 billion | $1.549 billion | Up 8% |
| Gross margin | 69.5% | 69.8% | Down 30 bps |
| Income from operations | $587.0 million | $612.8 million | Down 4% |
| Operating margin | 24.5% | 27.6% | Down 310 bps |
| Consolidated net income | $428.1 million | $457.4 million | Down 6% |
| Net income attributable to Illumina stockholders | $462.6 million | $461.6 million | Approximately flat |
| Diluted EPS | $3.07 | $3.10 | Down 1% |
| Cash flow from operations | $687.2 million | $659.6 million | Up 4% |
| Capital expenditures | $259.9 million | $142.8 million | Up 82% |
Revenue consisted of $2.032 billion of product revenue and $366.4 million of service and other revenue. Consumables revenue increased 21% to $1.544 billion, while instrument revenue declined 21% to $469.5 million. Service and other revenue increased 11% to $366.4 million.
At January 1, 2017, cash and cash equivalents were $734.5 million and short-term investments were $824.2 million, for combined cash, cash equivalents, and short-term investments of $1.559 billion. Approximately $749.7 million of this combined amount was held by foreign subsidiaries. Total debt principal consisted of $632.5 million of 0% convertible notes due 2019 and $517.5 million of 0.5% convertible notes due 2021. Management stated that available liquidity and expected operating cash flow were sufficient for near-term needs.
Total assets were $4.281 billion, total stockholders’ equity was $2.270 billion, and redeemable noncontrolling interests were $43.9 million. The company had no off-balance-sheet arrangements. It repurchased $249.3 million of common stock during fiscal 2016, with $100.7 million remaining under the authorization at year-end. No cash dividends have been paid or were planned.
Fourth-quarter information
For the fourth quarter of fiscal 2016, revenue was $619.3 million, gross profit was $419.4 million, consolidated net income was $107.5 million, net income attributable to Illumina stockholders was $123.8 million, and diluted EPS was $0.84. The comparable fourth quarter of fiscal 2015 included revenue of $591.5 million, consolidated net income of $102.9 million, stockholder net income of $104.5 million, and diluted EPS of $0.70.
Material changes versus the prior comparable period
- Revenue growth was driven primarily by the expanding sequencing installed base and higher consumables demand, while high-throughput instrument shipments declined.
- Product mix shifted toward consumables: consumables represented 64% of revenue versus 58% in fiscal 2015; instruments represented 20% versus 27%.
- Gross margin declined because of increased manufacturing capacity, partially offset by the higher consumables mix.
- Research and development expense increased 26% to $504.4 million, reflecting increased headcount, outside services, product development, and $43.0 million of additional consolidated VIE expense.
- Selling, general, and administrative expense increased 11% to $583.0 million, reflecting investments in personnel, facilities, and operational scale.
- Operating income declined despite revenue growth because operating expenses grew faster than revenue. Fiscal 2016 also included a $9.5 million reversal of prior legal-contingency expense related to patent litigation.
- Capital expenditures increased substantially, primarily for facilities, manufacturing capacity, and research and development equipment. Net property and equipment increased to $713.3 million from $342.7 million.
- Operating cash flow increased, but investing cash usage rose to $514.5 million because of higher capital expenditures, acquisitions, and investments. Financing cash usage declined to $204.7 million from $418.8 million, primarily because prior-period debt repayments were lower.
- Backlog increased to approximately $650 million from $560 million, with approximately two-thirds expected to ship during fiscal 2017; backlog remains subject to customer substitutions, delays, cancellations, and revenue-recognition requirements.
Guidance, outlook, commentary, risks, and unusual items
- Management expected revenue to continue increasing in fiscal 2017 and expected research and development and selling, general, and administrative expenses to continue growing.
- Illumina announced the NovaSeq 5000 and 6000 systems in January 2017. Product transitions may affect demand for existing systems, inventory levels, manufacturing costs, launch timing, and customer acceptance.
- GRAIL and Helix were consolidated VIEs and had no revenues. Consolidated VIE operating losses were $81.1 million in fiscal 2016 versus $8.4 million in fiscal 2015. GRAIL had received indications of interest for approximately $1 billion of Series B financing; if completed, Illumina expected its voting interest to fall below 20% and its remaining GRAIL investment to be accounted for under the cost method.
- GRAIL and Helix held $75.9 million of cash that was not available to settle Illumina’s obligations. Certain noncontrolling investors may have future redemption rights, including a Helix redemption right after January 1, 2021 under specified conditions.
- Illumina committed up to $100.0 million to a venture capital fund, of which $10.6 million had been funded or transferred during fiscal 2016. The remaining $89.5 million commitment was excluded from the contractual-obligations table because timing and amounts were uncertain.
- Contractual obligations totaled $2.333 billion, including $1.162 billion of debt obligations, $661.9 million of operating leases, and $376.9 million of build-to-suit leases. The table excluded $65.0 million of uncertain tax positions and $43.9 million of redeemable noncontrolling interests.
- Key risks include rapid technological change and competition, dependence on new product launches, manufacturing and single-source supplier constraints, regulatory approval and reimbursement uncertainty for clinical products, intellectual-property litigation, cybersecurity and data privacy, international currency exposure, research-funding variability, acquisition integration, and dependence on specialized personnel.
- The company settled litigation with Enzo for $21.0 million, allocating $11.5 million to a capitalized license and $9.5 million to past damages. The filing states that other pending litigation outcomes generally cannot be predicted and that losses exceeding recorded accruals could materially affect results.
- The company planned to adopt the new revenue standard beginning in fiscal 2018 and preliminarily expected no material impact, subject to completing its analysis. It also expected adoption of the stock-compensation standard in the first quarter of fiscal 2017, including a $46.4 million credit to retained earnings for unrealized excess tax benefits.
- Tax holidays and incentives in Singapore reduced fiscal 2016 tax expense by $32.1 million and increased diluted EPS by $0.22. The company had $65.0 million of gross uncertain tax positions and $849.2 million of undistributed foreign earnings intended to remain reinvested abroad.
Investor verification checklist
- Verify the sustainability of consumables-led growth and whether instrument demand recovers following the NovaSeq transition.
- Monitor gross-margin effects from expanded manufacturing capacity, pricing, product mix, royalties, and inventory provisions.
- Assess whether elevated research, development, sales, facilities, and VIE expenses translate into future revenue and operating-leverage gains.
- Review GRAIL’s financing, potential deconsolidation, ownership dilution, future funding requirements, and any resulting accounting changes.
- Evaluate liquidity after capital expenditures, share repurchases, lease commitments, debt maturities, venture-fund commitments, and potential noncontrolling-interest redemptions.
- Track regulatory, reimbursement, intellectual-property, litigation, cybersecurity, supplier, and foreign-exchange developments.
- Reconcile consolidated net income with net income attributable to Illumina stockholders, including the effect of consolidated VIE losses and noncontrolling interests.